US Edition
Published • loading... • Updated
Decoding Resistance to Targeted Therapy via New Cancer Models
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation epidermal growth factor receptor (EGFR) inhibitor used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. According to the researchers, the work addresses a critical challenge in oncology—treatment resistance that emerges over time. EGFR-mu…
1 Articles
1 Articles
Decoding Resistance to Targeted Therapy via New Cancer Models
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation epidermal growth factor receptor (EGFR) inhibitor used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. According to the researchers, the work addresses a critical challenge in oncology—treatment resistance that emerges over time. EGFR-mu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
